New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
09:26 EDTSFY, ARII, AKAM, BMRN, LPSN, HK, AMRN, MA, OTEX, YELP, WFM, YUMOn The Fly: Pre-market Movers
HIGHER: Amarin (AMRN), up 12% after positive mention by Adam Feuerstein of TheStreet. UP AFTER EARNINGS: MasterCard (MA), up 1%... Open Text (OTEX), up 11.5%... LivePerson (LPSN), up 14%... BioMarin (BMRN), up 6.4%... Halcon Resources (HK), up 2.3%... American Railcar (ARII), up 2.5%... Swift Energy (SFY), up 2%. DOWN AFTER EARNINGS: Akamai (AKAM), down 5.2%. LOWER: Whole Foods (WFM), down 5.8% after downgraded at UBS, JPMorgan following the company's lower than expected quarterly earnings results... Yelp (YELP), down 6%, downgraded at Raymond James after the company reported its Q2 results, which included a decline in its newly added businesses... Yum! Brands (YUM), down 6.5% after saying OSI scandal hurt China sales.
News For WFM;YELP;YUM;MA;AMRN;OTEX;LPSN;BMRN;HK;ARII;SFY;AKAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 25, 2015
16:24 EDTHKHalcon Resources reports Q4 EPS 5c, consensus 0c
Subscribe for More Information
16:21 EDTYELPYelp initiated with an Overweight at Morgan Stanley
Target $62.
16:12 EDTBMRNBioMarin sees 2015 revenue $840M-$870M, consensus $880.59M
On a constant currency basis, BioMarin revenue would have been between $885M-$915M. The company sees a 2015 GAAP loss ($360M)-($400M).
16:11 EDTBMRNBioMarin reports Q4 GAAP EPS (47c), consensus (59c)
Subscribe for More Information
15:05 EDTBMRNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include salesforce.com (CRM), consensus 14c... Avago Technologies (AVGO), consensus $1.94... L Brands (LB), consensus $1.80... Workday (WDAY), consensus (6c)... BioMarin (BMRN), consensus (59c)... Concho Resources (CXO), consensus 84c... Antero Resources (AR), consensus 28c... Medivation (MDVN), consensus $1.34... Transocean (RIG), consensus 77c... Sprouts Farmers Market (SFM), consensus 9c... SINA Corporation (SINA), consensus 18c.
06:14 EDTBMRNPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
15:59 EDTAKAMAkamai price target raised to $77 from $68 at Piper Jaffray
Subscribe for More Information
10:19 EDTAKAMAkamai to host investor meeting
Investor meeting to be held in Boston on February 24 from 8:30 until 2 pm. Webcast Link
10:06 EDTOTEXHigh option volume stocks
High option volume stocks: CHGG LBTYK SMH RCAP NGLS OTEX TERP CNC ALKS AMT
07:25 EDTMARW Baird to hold a conference
Subscribe for More Information
06:39 EDTMAVisa Europe announces 'tokenisation service'
Subscribe for More Information
February 23, 2015
16:27 EDTBMRNOn The Fly: Closing Wrap
Stocks on Wall Street began the session in negative territory and remained there for most of the session, with the Nasdaq the lone index to post a small gain. The Dow was weighed down by shares of Boeing (BA), which slid after the stock received a downgrade. There was little in the way of positive economic news, as the most notable report showed existing homes were lower than expected due to a shortage of inventory. The averages drifted for most of the session, as investors may be waiting on the sidelines ahead of tomorrow’s banking panel testimony by Fed Chair Janet Yellen. ECONOMIC EVENTS: In the U.S., the Chicago Fed national activity index rebounded to 0.13 in January, which was nearly in-line with expectations. Existing home sales dropped 4.9% to a 4.82M rate in January, which was much worse than the expected 1.8% drop to a 4.95M unit rate. In Europe, the Ifo Institute’s measure of German business confidence rose to 106.8 in February, which was up a tenth of a percentage point from the previous month but below the 107.7 consensus forecast. Also, the Bank of Israel became the latest central bank to cut rates this year, lowering its main interest rate to 0.1% from 0.25%. COMPANY NEWS: The shares of a number of health insurers rose after the Centers for Medicare and Medicaid Services, or CMS, issued preliminary 2016 Medicare Advantage rates. According to Credit Suisse, the rates were favorable for the insurers. Following the CMS announcement made late Friday, Humana (HUM) climbed $8.40, or 5.38%, to $164.52, UnitedHealth (UNH) rose $3.78, or 3.36%, to $116.40, and WellCare (WCG) gained $4.68, or 5.53%, to $89.30. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which jumped $9.77, or 17.7%, to $64.96 after Reuters said the company is working with financial advisers to explore a potential sale after receiving takeover interest from several companies including Shire (SHPG) and BioMarin (BMRN). Also higher was Valeant (VRX), which rose $25.49, or 14.71%, to $198.75 after the company agreed to buy Salix (SLXP) for $158 per share and also reported better-than-forecast earnings. Salix shares, however, fell $2.09, or 1.32%, to $155.76, as a report Friday from CNBC's David Faber telegraphed the deal and suggested Valeant could value Salix around $160 per share. Among the noteworthy losers was Spectrum Pharmaceuticals (SPPI), which dropped $1.18, or 15.82%, to $6.28 after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. Also lower were shares of Boeing, which fell $3.57, or 2.26%, to $154.74 after the stock was downgraded to Sell from Neutral at Goldman Sachs. INDEXES: The Dow fell 23.60, or 0.13%, to 18,116.84, the Nasdaq gained 5.01, or 0.1%, to 4,960.97, and the S&P 500 slipped 0.64, or 0.03%, to 2,109.66.
16:03 EDTOTEXOpenText says CEO diagnosed with Leukemia
OpenText announced that Mark Barrenechea, its President and CEO, has been diagnosed with Leukemia, the treatment of which will require him to reduce his involvement in the day-to-day operations of the company for approximately the next 100 days. During this time, a CEO Operating Committee has been established to assist in the management of the company's day-to-day operations. In addition to Barrenechea, the CEO Operating Committee will consist of John Doolittle, CFO, and Gordon Davies, Chief Legal Officer. Barrenechea remains CEO and a Director during this time, and will continue to be involved in the company's strategic matters.
12:29 EDTBMRNPTC Therapeutics exploring potential sale, Reuters reports
Subscribe for More Information
06:14 EDTWFMWhole Foods to host investor meeting
Investor meeting to be held on February 27 at 9 am. Webcast Link
February 20, 2015
16:03 EDTAMRNOptions Update; February 20, 2015
Subscribe for More Information
10:20 EDTAMRNHigh option volume stocks
Subscribe for More Information
09:49 EDTYELPYelp initiated with a Buy at Rosenblatt
Subscribe for More Information
09:38 EDTAMRNActive equity options trading on open
Subscribe for More Information
08:34 EDTYELPYelp suing companies over fake positive reviews, NY Post says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use